Three Arch Partners
VC Fund
Portola Valley, United States
Three Arch Partners is a VC fund in Portola Valley focused on Health Care and Biotechnology. Three Arch Partners was formed in 1993 to provide young companies with access to relevant clinical and business resources, as well as capital. Three Arch has helped create, build and fund more than 100 important new healthcare companies. These companies have often become the clinical and market leaders in their respective fields, and have generatedstrong returns. The fund focuses on opportunities in medical devices and healthcare services, and less frequently in biotechnology.
- Total investments:
- 75
- Last investment:
- Lead investor:
- 16%
- Fund size:
- $450M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Three Arch Partners invests in
Stages Three Arch Partners invests in
Countries Three Arch Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 6 contacts → | |||
Investment Focus
Industry
- Health Care 42 (56%)
- Biotechnology 28 (37%)
- Medical Device 23 (31%)
- Medical 21 (28%)
- Manufacturing 7 (9%)
Stage
- Series B 15 (20%)
- Series C 15 (20%)
- Series D 11 (15%)
- Funding Round 11 (15%)
- Series A 8 (11%)
Country
- United States 49 (65%)
- Belgium 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Barclay Nicholson
Administrative Partner
|
Administrative Partner | Total investments: 0 | Find email | |
Mark Wan
Managing Director
|
Managing Director | Total investments: 13 | Find email | |
Richard Lin
Partner
|
Partner | Total investments: 0 | Find email | |
Rod Young
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Stephen Bonelli
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Neuronetics is focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. They are the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment. | $15M / Series G / Jun 06, 2017 | ||
| Neuronetics is focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. They are the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment. | $34.3M / Series F / Apr 27, 2015 | ||
| Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza systemis the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro. | Series C / Mar 07, 2013 | ||
| Access Closure, Inc., a medical device company, provides access site management products to address the complex challenge of vascular closure during interventional and diagnostic procedures. The company's products include Mynx delivery system, a vascular closure device that seals the arteriotomy using a water-soluble and extravascular sealant,which expands in the tissue tract by absorbing blood and subcutaneous fluids. Access Closure, Inc. was founded in 2002 and is based in Mountain View, California. | $998.1K / Oct 01, 2012 | ||
| Access Closure, Inc., a medical device company, provides access site management products to address the complex challenge of vascular closure during interventional and diagnostic procedures. The company's products include Mynx delivery system, a vascular closure device that seals the arteriotomy using a water-soluble and extravascular sealant,which expands in the tissue tract by absorbing blood and subcutaneous fluids. Access Closure, Inc. was founded in 2002 and is based in Mountain View, California. | $2.8M / Jan 01, 2012 | ||
| Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza systemis the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro. | Series B / Jul 19, 2011 | ||
| Crux Biomedical, Inc., was formed in August 2004 by physicians Tom Fogarty and Frank Arko based upon their observations of the clinical limitations of current vena cava filters. | $12M / Series C / Jun 07, 2011 | ||
| Neuronetics is focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. They are the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment. | Series E / May 16, 2011 | ||
| Respicardia (formerly Cardiac Concepts) is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing patternduring sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time™. | $27M / Series C / Aug 25, 2010 | ||
| Founded in 1998 by Stanford graduate students, Ingenuity Systems is a company that is taking on the challenge of next-generation knowledge management for the life sciences community. It's long term focus on innovation in semantic search, ontology, and software development has created groundbreaking technologies that help life scienceresearchers more effectively search, explore, visualize, and analyze biological and chemical findings related to genes, proteins, and small molecules (e.g. drugs).All Ingenuity products, solutions, and services leverage the Ingenuity Knowledge Base - a repository of biological interactions and functional annotations created from millions of individually modeled relationships between proteins, genes, complexes, cells, tissues, metabolites, drugs, and diseases. These relationships include rich contextual details and are reviewed for accuracy. Products:IPA®, is software that helps researchers integrate and analyze complex 'omics data. IPA helps researchers understand biology at multiple levels by integrating data from a variety of experimental platforms and providing insight into the molecular and chemical interactions, cellular phenotypes, and disease processes of a biological system. IPA intelligently searches the Ingenuity®Knowledge Base for information on genes, proteins, chemicals, drugs, and molecular relationships to build biological models or get up to speed in a relevant area of research. IPA provides the right biological context to facilitate informed decision-making, advance research project design, and generate new testable hypotheses.Ingenuity® iReport(TM) is the fastest way to understand the biological meaning of expression data. It combines biological and statistical analysis for a rapid and accurate analysis of what genes are significantly differentially expressed in a dataset, and summarizes the affected biology. iReport includes novel interactive & visual tools that help researchers quickly identify the most interesting subset of genes for follow-up.Ingenuity(R) Variant Analysis(TM) combines analytical tools and integrated content to help researchers rapidly identify a short list of compelling variants from human resequencing data using selection criteria based both upon published biological evidence and their own knowledge of disease biology.Ingenuity is headquartered in Redwood City, California and has offices in Germany, Switzerland, France, the United Kingdom, and Japan. | $15.4M / Jul 01, 2010 | ||
| See all 75 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Three Arch Partners invest in?
Three Arch Partners invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series B and Series C stage. Most of the 75 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Three Arch Partners?
Public channels for Three Arch Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Three Arch Partners?
The team at Three Arch Partners includes Barclay Nicholson (Administrative Partner), Mark Wan (Managing Director) and Richard Lin (Partner), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
